using the F-codes in the ICD-10 diagnosis system; therefore it is not possible to collect data on specific substances, but only on large drug categories (e.g. opioids, stimulants, etc.). Most data included in the TDI Protocol ver.3.0 are not included in the Norwegian monitoring system. Limitations Some limitations are found in the Norwegian monitoring system. The most relevant are related to the limited implementation of the TDI Protocol and the reporting to the EMCDDA on few basic variables. Furthermore some parts of the drug treatment system are not covered; even they play an important role in drug treatment in Norway (e.g. GPs). However it has to be considered that Norway only since 2010 has started its participation in the EMCDDA TDI monitoring system, which may have caused some delay in the full implementation of the European standards. Bibliographic reference "Guidelines for registering within specialized treatment for substance abusers (TSB)" (IS-1787 - Guidelines) the Directorate of Health 2010 Poland Sources: Reports, 2015 National Report, National TDI expert The National monitoring system: description Information on the number of individuals admitted to drug treatment for drug addiction in is collected by the National Bureau for Drug Prevention (that has also the role of Polish National Point) through a centralised system of electronic or paper based data reporting from the treatment centres. The system has been implemented since 2008. The National Focal Point collects data on clients in treatment in the framework of the treatment demand indicator (TDI), which was a pilot project until the end of 2013. Following an Act of Law and Ordinance of the Minister of Health, it has become obligatory for treatment facilities to collect TDI data since January 2014. Another relevant source of data on drug patients is the and Neurology (IPiN) that has been collecting data since many years from residential treatment on people with drug related problems. However the data collected by the IPiN are not in line with the EMCDDA guidelines. Coverage: The data coverage is national, but limited. It is hard to estimate coverage because we have only National Bureau for Drug Prevention booklet with information treatment centres in Poland as the reference point (benchmark). There are not all treatment centres in the booklet. We have found
using the F-codes in the ICD-10 diagnosis system; therefore it is not possible to collect data on specific substances, but only on large drug categories (e.g. opioids, stimulants, etc.). Most data included in the TDI Protocol ver.3.0 are not included in the Norwegian monitoring system. Limitations Some limitations are found in the Norwegian monitoring system. The most relevant are related to the limited implementation of the TDI Protocol and the reporting to the EMCDDA on few basic variables. Furthermore some parts of the drug treatment system are not covered; even they play an important role in drug treatment in Norway (e.g. GPs). However it has to be considered that Norway only since 2010 has started its participation in the EMCDDA TDI monitoring system, which may have caused some delay in the full implementation of the European standards. Bibliographic reference "Guidelines for registering within specialized treatment for substance abusers (TSB)" (IS-1787 - Guidelines) the Directorate of Health 2010 Poland Sources: Reports, 2015 National Report, National TDI expert The National monitoring system: description Information on the number of individuals admitted to drug treatment for drug addiction in is collected by the National Bureau for Drug Prevention (that has also the role of Polish National Point) through a centralised system of electronic or paper based data reporting from the treatment centres. The system has been implemented since 2008. The National Focal Point collects data on clients in treatment in the framework of the treatment demand indicator (TDI), which was a pilot project until the end of 2013. Following an Act of Law and Ordinance of the Minister of Health, it has become obligatory for treatment facilities to collect TDI data since January 2014. Another relevant source of data on drug patients is the and Neurology (IPiN) that has been collecting data since many years from residential treatment on people with drug related problems. However the data collected by the IPiN are not in line with the EMCDDA guidelines. Coverage: The data coverage is national, but limited. It is hard to estimate coverage because we have only National Bureau for Drug Prevention booklet with information treatment centres in Poland as the reference point (benchmark). There are not all treatment centres in the booklet. We have found
att_248912_EN_Methodological_information_by%20country%202016%20Final.docx